Replies to post #143926 on Biotech Values

[biomaven0]

NICE is indeed the standard investors should be watching

If that's your belief, then it's hard to see the logic for investing in biotech at all. Do you think NICE will pay for the new HCV drugs? Or Vertex's new cystic fibrosis drug? Or even Amarin's EPA pill at the lower end of the pricing spectrum?

Peter

[DewDiligence]

NICE requests more data on Roche’s Zelboraf before agreeing to reimburse at lower rate:

http://www.bloomberg.com/news/2012-08-09/roche-s-skin-cancer-treatment-delayed-by-u-k-drug-cost-a.html

NICE, which advises the state-run National Health Service on the treatments that represent value for money, refused to back Zelboraf for approval after the first consultation in June [#msg-76635851]. Roche offered to cut the price of the drug, which costs about 1,750 pounds ($2,734) a week in the U.K. The average duration of treatment is seven months, which would cost 52,500 pounds, NICE said. The amount of the offered discount is confidential, the authority said.

[DewDiligence]

NICE rejects Opdivo reimbursement in second-line NSCLC:

http://www.reuters.com/article/us-bristol-myers-cancer-britain-idUSKBN0TZ1HT20151216

In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence (NICE) said using Opdivo, or nivolumab, in non-small cell lung cancer after chemotherapy did not represent a cost-effective use of resources.

[DewDiligence]

NICE rejects Imbruvica for CLL:

http://www.pharmatimes.com/Article/16-03-02/NICE_turns_down_Janssen_s_Imbruvica_for_CLL.aspx

[DewDiligence]

NICE declines to reimburse Roche’s Perjeta:

http://www.reuters.com/article/us-roche-britain-idUSKCN0YA332

[DewDiligence]

NICE seeks to expedite endorsement of drugs with lowest cost/QALY:

http://www.reuters.com/article/us-pharmaceuticals-britain-nice-idUSKCN12D2A7

The National Institute for Health and Care Excellence (NICE) said on Thursday that treatments offering exceptional value for money could be cleared for National Health Service use nearly three months earlier than at present under the new process.

The system will apply to treatments with a likely cost per quality adjusted life year (QALY) of up to…[$12,500]. For these products, final NICE guidance would be published immediately after a drug wins its official marketing license.

$12,500/QALY is a stringent threshold, so it seems doubtful that many new drugs will be efficacious, tolerable, and cheap enough to meet it.